Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults

Abstract Background The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial virus (RSV) disease with acceptable safety in adults aged ≥60 years in the ConquerRSV trial. Here, humoral immunogenicity results from the trial are presented. Methods This phase 2/3 trial randomly assigned...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 230; no. 5; pp. e996 - e1006
Main Authors:	Goswami, Jaya, Baqui, Abdullah H, Doreski, Pablo A, Perez Marc, Gonzalo, Jimenez, Gilberto, Ahmed, Salahuddin, Zaman, Khalequz, Duncan, Christopher J A, Ujiie, Mugen, Rämet, Mika, Pérez–Breva, Lina, Lan, Lan, Du, Jiejun, Kapoor, Archana, Mehta, Shraddah, Tomassini, Joanne E, Huang, Wenmei, Zhou, Honghong, Stoszek, Sonia K, Priddy, Frances, Lin, Nina, Le Cam, Nancy, Shaw, Christine A, Slobod, Karen, Wilson, Eleanor, Miller, Jacqueline M, Das, Rituparna
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 15.11.2024
Subjects:	Aged Aged, 80 and over Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Double-Blind Method Female Humans Immunity, Humoral Immunogenicity, Vaccine Male Middle Aged mRNA Vaccines Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - administration & dosage Respiratory Syncytial Virus Vaccines - genetics Respiratory Syncytial Virus Vaccines - immunology Respiratory Syncytial Virus, Human - genetics Respiratory Syncytial Virus, Human - immunology neutralizing antibody binding antibody RSV mRNA-1345 immunogenicity
ISSN:	0022-1899, 1537-6613, 1537-6613
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!